You are here

Merck

Padding its lung cancer lead, Merck's Keytruda helped PD-L1 patients live 30 months longer

Fierce Pharma

Wed, 10/18/17 - 10:29 am

Despite notable failures, cancer vaccines are poised for a leap onto the market: expert

Fierce Pharma

Wed, 10/18/17 - 09:06 am

cancer vaccines

Bristol-Myers Squibb

Merck targets high-risk military veterans for hepatitis C lessons

Fierce Pharma

Mon, 10/16/17 - 11:55 am

Positive PhIII can’t salvage Merck’s anacetrapib, now relegated to the scrap heap

Endpoints

Wed, 10/11/17 - 11:05 pm

clinical trials

CETP inhibitors

[forum discussion]What's up in Oncology?

Cafepharma Message Boards

Wed, 10/11/17 - 09:59 am

Merck's Gardasil 9 offers at least 6 years of cancer protection, data show

Fierce Pharma

Tue, 10/10/17 - 11:10 pm

cervical cancer

Giant Merck buddies up with little KalVista on lead drug, igniting stock with a $760M deal

Endpoints

Tue, 10/10/17 - 09:50 am

diabetic macular edema

Roche's Tecentriq cedes bladder-cancer share to Keytruda in wake of trial misfire

Fierce Pharma

Sat, 10/7/17 - 11:04 am

‘Going big’: Merck launches frontline PhIII lung cancer study for Keytruda/Yervoy combo

Endpoints

Fri, 10/6/17 - 11:41 am

Bristol-Myers Squibb

Most new cancer meds haven't proved they can improve or extend lives: study

Fierce Pharma

Thu, 10/5/17 - 09:38 am

Promising Ebola vaccines from Merck, Johnson & Johnson win BARDA funding

Fierce Pharma

Mon, 10/2/17 - 10:12 pm

Merck Hepatitis C exit could lift the space’s two remaining drugmakers

Marketwatch

Sun, 10/1/17 - 10:04 am

Gilead Sciences

The hep C pipeline shrivels as Merck dumps two next-gen combos, boosting leader Gilead

Endpoints

Fri, 09/29/17 - 10:03 am

Merck's Keytruda resumes regulatory hot streak with stomach cancer approval

Fierce Pharma

Mon, 09/25/17 - 07:28 pm

Pharma executives wary of value-based deals, but see the potential benefits: PwC

Fierce Pharma

Fri, 09/22/17 - 11:13 am

value-based contracts

House committee wants to know a lot more about the cyberattack that damaged Merck

Endpoints

Fri, 09/22/17 - 09:11 am

2 Important Dates for Big Pharma

Yahoo/GuruFocus

Wed, 09/20/17 - 11:15 pm

Bristol-Myers Squibb

Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars

Drug Channels

Wed, 09/20/17 - 09:05 am

The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017

Motley Fool

Mon, 09/18/17 - 10:53 am

cancer immunotherapies

Bristol-Myers Squibb

Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?

Motley Fool

Sat, 09/16/17 - 12:01 pm

Bristol-Myers Squibb

Pages